Oruka Therapeutics (ORKA) announced that the U.S. FDA cleared its investigational new drug, IND, application for its Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, called EVERLAST-A. “We’re thrilled by this rapid progress into Phase 2 development, and very excited to start our first psoriasis study,” said Lawrence Klein, PhD, CEO of Oruka. “We think that ORKA-001 can redefine the standard of care in this important disease with potential for once per year dosing, off-treatment remissions and higher rates of disease clearance.” The Company expects to share efficacy and response duration data from EVERLAST-A in 2H 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA:
- Oruka Therapeutics: A Promising Contender in the $30 Billion Psoriasis Market with Innovative Treatments ORKA-001 and ORKA-002
- Oruka Therapeutics Appoints New Chief Operating Officer
- Oruka Therapeutics Holds Annual Stockholders Meeting
- Oruka Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating
- Oruka Therapeutics initiated with a Buy at BTIG